Bifalgorithm post · Research cancer 2025 · Detecting Minimal Residual Disease and Recurrence

Recurrence Monitoring

Recurrence Monitoring (Research cancer 2025 · Detecting Minimal Residual Disease and Recurrence) — "In another study in melanoma, ctDNA detected after surgery…

Ideas in this flowchart

  • ctDNA liquid biopsy helps personalize posttreatment cancer care
  • Posttreatment ctDNA status can stratify recurrence and survival risk
  • In melanoma, ctDNA detected after surgery identified patients at highest risk of recurrence (Syeda et al., 2025)
  • In melanoma, continued ctDNA presence during follow-up signaled early relapse and poor survival despite standard therapy
  • In cervical cancer, a phase III trial showed that posttreatment ctDNA predicted relapse and survival (Mayadev et al., 2025)
  • Personalized ctDNA tests detected signs of recurrence months before they appeared on scans
  • Patients with detectable ctDNA after treatment were significantly more likely to experience relapse
  • Liquid biopsy approaches help clinicians personalize posttreatment care
  • Liquid biopsy offers a less invasive and highly sensitive tool for detecting recurrence
  • ctDNA findings support planning of clinical care
Bifalgorithm
Sign up
Feed/

Recurrence Monitoring

No cover

Channel

Research cancer 2025

1 page

U
USR292600b83e2a
Ebook2w

"In another study in melanoma, ctDNA detected after surgery identified patients at highest risk of recurrence, and its continued presence during follow-up treatment signaled early relapse and poor survival despite standard therapy (1089)Syeda MM, et al. (2025) Lancet Oncol, 26: 641.. In cervical cancer, results from a phase III clinical trial showed that detection of ctDNA after treatment predicted relapse and survival. Personalized ctDNA tests could detect signs of cancer recurrence months before it appeared on scans, while patients with detectable ctDNA after treatment were significantly more likely to experience relapse (1090)Mayadev J, et al. (2025) Ann Oncol.. These studies demonstrate how liquid biopsy approaches are helping clinicians personalize posttreatment care, offering a less invasive, highly sensitive tool to detect recurrence and plan clinical care."

Flowchart preview
👍
0
0 comments0 shares

Sign in to view and post comments.